| Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label … H Saito, T Fukuhara, N Furuya, K Watanabe, S Sugawara, S Iwasawa, ... The Lancet Oncology 20 (5), 625-635, 2019 | 579 | 2019 |
| Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M–mutated non–small cell lung cancer previously treated with epidermal growth factor receptor … H Akamatsu, Y Toi, H Hayashi, D Fujimoto, M Tachihara, N Furuya, ... JAMA oncology 7 (3), 386-394, 2021 | 135 | 2021 |
| Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of … Y Kawashima, T Fukuhara, H Saito, N Furuya, K Watanabe, S Sugawara, ... The Lancet Respiratory Medicine 10 (1), 72-82, 2022 | 80 | 2022 |
| Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026. N Furuya, T Fukuhara, H Saito, K Watanabe, S Sugawara, S Iwasawa, ... Journal of Clinical Oncology 36 (15_suppl), 9006-9006, 2018 | 79 | 2018 |
| A phase 2 study of atezolizumab for pretreated NSCLC with idiopathic interstitial pneumonitis S Ikeda, T Kato, H Kenmotsu, T Ogura, S Iwasawa, Y Sato, T Harada, ... Journal of Thoracic Oncology 15 (12), 1935-1942, 2020 | 66 | 2020 |
| NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations. M Maemondo, T Fukuhara, H Saito, N Furuya, K Watanabe, S Sugawara, ... Journal of Clinical Oncology 38 (15_suppl), 9506-9506, 2020 | 65 | 2020 |
| Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and … Y Ito, T Tsuda, H Minatogawa, S Kano, K Sakamaki, M Ando, K Tsugawa, ... Journal of Clinical Oncology 36 (10), 1000-1006, 2018 | 65 | 2018 |
| The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer H Izumi, S Matsumoto, J Liu, K Tanaka, S Mori, K Hayashi, S Kumagai, ... Nature 600 (7888), 319-323, 2021 | 57 | 2021 |
| Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression A Tanimoto, S Matsumoto, S Takeuchi, S Arai, K Fukuda, A Nishiyama, ... Clinical Cancer Research 27 (5), 1410-1420, 2021 | 41 | 2021 |
| A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903 K Ito, M Morise, K Wakuda, O Hataji, T Shimokawaji, K Takahashi, ... ESMO open 6 (3), 100115, 2021 | 40 | 2021 |
| Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non‐small cell lung cancer K Kakinuma, H Tsuruoka, K Morikawa, N Furuya, T Inoue, T Miyazawa, ... Thoracic Cancer 9 (1), 99-104, 2018 | 40 | 2018 |
| Cell therapy with adipose tissue-derived stem/stromal cells for elastase-induced pulmonary emphysema in rats N Furuya, M Takenaga, Y Ohta, Y Tokura, A Hamaguchi, A Sakamaki, ... Regenerative medicine 7 (4), 503-512, 2012 | 27 | 2012 |
| Appearance of a BRAF mutation conferring resistance to crizotinib in non–small cell lung cancer harboring oncogenic ROS1 fusion J Watanabe, N Furuya, Y Fujiwara Journal of Thoracic Oncology 13 (4), e66-e69, 2018 | 26 | 2018 |
| IgG4-related pleural disease presenting as a massive bilateral effusion A Ishida, N Furuya, T Nishisaka, M Mineshita, T Miyazawa Journal of Bronchology & Interventional Pulmonology 21 (3), 237-241, 2014 | 25 | 2014 |
| Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study T Fukuhara, H Saito, N Furuya, K Watanabe, S Sugawara, S Iwasawa, ... EBioMedicine 57, 2020 | 24 | 2020 |
| Real‐world efficacy of atezolizumab in non‐small cell lung cancer: a multicenter cohort study focused on performance status and retreatment after failure of anti‐PD‐1 antibody N Furuya, M Nishino, K Wakuda, S Ikeda, T Sato, R Ushio, S Tanzawa, ... Thoracic Cancer 12 (5), 613-618, 2021 | 22 | 2021 |
| Current status of clinical proteogenomics in lung cancer T Nishimura, H Nakamura, Á Végvári, G Marko-Varga, N Furuya, H Saji Expert Review of Proteomics 16 (9), 761-772, 2019 | 22 | 2019 |
| Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L) H Akamatsu, S Teraoka, S Takamori, S Miura, H Hayashi, A Hata, Y Toi, ... Clinical Cancer Research 28 (15), 3207-3213, 2022 | 21 | 2022 |
| A randomized comparison of nivolumab versus Nivolumab+ docetaxel for previously treated advanced or recurrent ICI-naïve non–small cell lung cancer: torg1630 Y Taniguchi, T Shimokawa, Y Takiguchi, T Misumi, Y Nakamura, ... Clinical Cancer Research 28 (20), 4402-4409, 2022 | 20 | 2022 |
| Suitability of transbronchial brushing cytology specimens for next‐generation sequencing in peripheral lung cancer N Furuya, S Matsumoto, K Kakinuma, K Morikawa, T Inoue, H Saji, K Goto, ... Cancer Science 112 (1), 380-387, 2021 | 19 | 2021 |
